Revenue

12 Months Ended

Jan. 03, 2021

Revenue from Contract with Customer [Abstract]

Revenue

2. REVENUE

Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements.

Revenue by Source

	2020						2019						2018
in millions	Sequencing		Microarray		Total		Sequencing		Microarray		Total		Sequencing		Microarray		Total
Consumables	$	2,039	$	265	$	2,304	$	2,075	$	317	$	2,392	$	1,824	$	353	$	2,177
Instruments	417		14		431		517		20		537		535		37		572
Total product revenue	2,456		279		2,735		2,592		337		2,929		2,359		390		2,749
Service and other revenue	423		81		504		476		138		614		416		168		584
Total revenue	$	2,879	$	360	$	3,239	$	3,068	$	475	$	3,543	$	2,775	$	558	$	3,333

Revenue by Geographic Area

Based on region of destination (in millions)	2020		2019		2018
Americas (1)	$	1,744	$	1,970	$	1,864
Europe, Middle East, and Africa	886		933		851
Greater China (2)	342		372		365
Asia-Pacific	267		268		253
Total revenue	$	3,239	$	3,543	$	3,333

(1) Revenue for the Americas region included United States revenue of $1,655 million, $1,859 million, and $1,779 million in 2020, 2019, and 2018, respectively.

(2) Region includes revenue from China, Taiwan, and Hong Kong.

Performance Obligations

We regularly enter into contracts with multiple performance obligations. Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of January 3, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $816 million, of which approximately 90% is expected to be converted to revenue through 2021, approximately 7% in the following twelve months, and the remainder thereafter.

Contract Liabilities

Contract liabilities, which consist of deferred revenue and customer deposits, as of January 3, 2021 and December 29, 2019 were $230 million and $209 million, respectively, of which the short-term portions of $186 million and $167 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in 2020 included $156 million of previously deferred revenue that was included in contract liabilities as of December 29, 2019.